Novocure Ltd

NASDAQ NVCR

Download Data

Novocure Ltd Days in Inventory 3 year CAGR for the quarter ending March 31, 2024: 10.28%

Novocure Ltd Days in Inventory 3 year CAGR is 10.28% for the quarter ending March 31, 2024, a 114.50% change year over year. The days in inventory ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing 365 by the ratio of cost of revenue to the average of inventory and other current assets. This ratio indicates the efficiency of inventory management and the company's ability to convert inventory into sales within a specific period. A lower number of days in inventory is generally preferable. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Novocure Ltd Days in Inventory for the quarter ending March 31, 2023 was 199.66, a 1.21% change year over year.
  • Novocure Ltd Days in Inventory for the quarter ending March 31, 2022 was 197.28, a -27.60% change year over year.
  • Novocure Ltd Days in Inventory for the quarter ending March 31, 2021 was 272.51, a 57.07% change year over year.
  • Novocure Ltd Days in Inventory for the quarter ending March 31, 2020 was 173.50, a -28.19% change year over year.
NASDAQ: NVCR

Novocure Ltd

CEO Mr. William F. Doyle
IPO Date Oct. 2, 2015
Location Jersey
Headquarters No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees 1,453
Sector Healthcare
Industry Medical devices
Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Similar companies

INMD

InMode Ltd

NA

NA

IRTC

iRhythm Technologies Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email